These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 33955240)
1. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig Kobayashi RH; Mandujano JF; Rehman SM; Kobayashi AL; Geng B; Atkinson TP; Melamed I; Turpel-Kantor E; Clodi E; Gupta S Immunotherapy; 2021 Jul; 13(10):813-824. PubMed ID: 33955240 [No Abstract] [Full Text] [Related]
2. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies. Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J Front Immunol; 2019; 10():40. PubMed ID: 30778345 [No Abstract] [Full Text] [Related]
3. Efficacy and safety of octanorm (cutaquig Latysheva E; Rodina Y; Sizyakina L; Totolian A; Tuzankina I Immunotherapy; 2020 Apr; 12(5):299-309. PubMed ID: 32212944 [No Abstract] [Full Text] [Related]
4. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies. Kobayashi RH; Litzman J; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Höller S; Turpel-Kantor E; Kreuwel H; Speer JC; Gupta S Clin Exp Immunol; 2022 Dec; 210(2):91-103. PubMed ID: 36208448 [TBL] [Abstract][Full Text] [Related]
5. Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J Front Immunol; 2022; 13():1110388. PubMed ID: 36605207 [TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency. Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Borte M; Bernatowska E; Ochs HD; Roifman CM; Clin Exp Immunol; 2011 Jun; 164(3):357-64. PubMed ID: 21413943 [TBL] [Abstract][Full Text] [Related]
8. Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Paris K; Haddad E; Borte M; Brodszki N; Dérfalvi B; Maródi L; Hussain I; Darter A; Engl W; Leibl H; McCoy B; Yel L Immunotherapy; 2019 Apr; 11(5):397-406. PubMed ID: 30626238 [TBL] [Abstract][Full Text] [Related]
9. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies. Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K Front Immunol; 2020; 11():981. PubMed ID: 32670265 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder. Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716 [No Abstract] [Full Text] [Related]
11. Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. Perez EE; Hébert J; Ellis AK; Alpan O; Lumry WR; Shapiro R; Suez D; Mandujano JF; Wasserman RL Front Immunol; 2021; 12():707463. PubMed ID: 34305948 [TBL] [Abstract][Full Text] [Related]
16. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. Borte M; Pac M; Serban M; Gonzalez-Quevedo T; Grimbacher B; Jolles S; Zenker O; Neufang-Hueber J; Belohradsky B J Clin Immunol; 2011 Oct; 31(5):752-61. PubMed ID: 21674136 [TBL] [Abstract][Full Text] [Related]
18. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction. Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367 [TBL] [Abstract][Full Text] [Related]
19. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies. Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G; Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588 [TBL] [Abstract][Full Text] [Related]